GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...

Nine months out from landing $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has ...

Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

FOR IMMEDIATE RELEASERelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and ...

Relation announced two multi-program strategic collaborations with GSK (GSK). The collaborations will focus on the identification and ...

Mishcon de Reya advises Relation on two strategic collaborations with GSK to advance therapeutics development for diseases ...

Relation Therapeutics and GSK signed two contracts to discover and develop new therapeutic targets to treat osteoarthritis and fibrotic disease.

As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.

UK-based biotech Relation Therapeutics today announced two multi-program strategic collaborations with pharma major GSK. The ...

Relation Therapeutics Ltd. has delivered the first commercial validation of its combined wet lab/in silico platform for ...

The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies ...